Mark Cobbold
Overview
Explore the profile of Mark Cobbold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
2151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barrett A, Britton Z, Carrasco R, Breen S, Broggi M, Hatke A, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5413-5429.
PMID: 39321207
Purpose: Claudin 18.2 (CLDN18.2) is a surface membrane protein that is crucial for maintaining tight junctions in gastric mucosal cells and is highly expressed in gastric, esophageal, and pancreatic cancers....
2.
Zhang S, Yan C, Millar D, Yang Q, Heather J, Langenbucher A, et al.
Cancer Res
. 2024 May;
84(9):1534.
PMID: 38693893
No abstract available.
3.
Hardaker E, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, et al.
Nat Commun
. 2024 Feb;
15(1):1700.
PMID: 38402224
The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here...
4.
Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold J, et al.
J Clin Invest
. 2023 Nov;
133(22).
PMID: 37966111
Prostate cancer is generally considered an immunologically "cold" tumor type that is insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent antitumor immune response...
5.
Heather J, Spindler M, Alonso M, Shui Y, Millar D, Johnson D, et al.
Nucleic Acids Res
. 2022 Mar;
50(12):e68.
PMID: 35325179
The study and manipulation of T cell receptors (TCRs) is central to multiple fields across basic and translational immunology research. Produced by V(D)J recombination, TCRs are often only recorded in...
6.
Zhang S, Yan C, Millar D, Yang Q, Heather J, Langenbucher A, et al.
Cancer Res
. 2021 Dec;
82(5):773-784.
PMID: 34965933
Significance: This study develops a high-throughput preclinical platform to identify patient-specific antibody-peptide epitope conjugates that target cancer cells and demonstrates the potential of this immunotherapy approach for treating ovarian carcinoma.
7.
Penny S, Abelin J, Malaker S, Myers P, Saeed A, Steadman L, et al.
Front Immunol
. 2021 Sep;
12:723566.
PMID: 34504498
There is a pressing need for novel immunotherapeutic targets in colorectal cancer (CRC). Cytotoxic T cell infiltration is well established as a key prognostic indicator in CRC, and it is...
8.
Yan C, Yang Q, Zhang S, Millar D, Alpert E, Do D, et al.
J Exp Med
. 2021 Aug;
218(10).
PMID: 34415995
T cell immunotherapies have revolutionized treatment for a subset of cancers. Yet, a major hurdle has been the lack of facile and predicative preclinical animal models that permit dynamic visualization...
9.
Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren M, Kossenkov A, et al.
Clin Cancer Res
. 2021 Aug;
27(21):5961-5978.
PMID: 34407972
Purpose: To evaluate the mechanisms of how therapeutic upregulation of the transcription factor, CCAAT/enhancer-binding protein alpha (C/EBPα), prevents tumor progression in patients with advanced hepatocellular carcinoma (HCC) and in different...
10.
Mao S, Chaerkady R, Yu W, DAngelo G, Garcia A, Chen H, et al.
Mol Cancer Ther
. 2021 Mar;
20(3):541-552.
PMID: 33653945
Resistance to antibody-drug conjugates (ADCs) has been observed in both preclinical models and clinical studies. However, mechanisms of resistance to pyrrolobenzodiazepine (PBD)-conjugated ADCs have not been well characterized and thus,...